(Q37385373)

20 August 2017

1 reference

title

Novel anti-tubulin cytotoxic agents for breast cancer (English)

1 reference

20 August 2017

0 references

1 reference

Patrick G Morris

1

1 reference

PubMed ID

19192956

20 August 2017

Monica N Fornier

series ordinal

2

1 reference

20 August 2017

1 February 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

2

1 reference

20 August 2017

175-185

1 reference

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

20 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Epothilones in breast cancer: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Preclinical evaluation of new taxoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase II study of vinflunine in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Microtubule active agents: beyond the taxane frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.175

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.49.560

Identifiers

DOI

10.1586/14737140.9.2.175

1 reference

20 August 2017

1 reference

PubMed ID

19192956